Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 14/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751992 | 0.75 | FDPS (0.43) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL14675467 | 0.75 | FDPS (0.52) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL10630314 | 0.74 | FDPS (0.42) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL9502919 | 0.71 | FDPS (0.40) | FDPSGGPS1LPAR1LPAR3 | |
| SCHEMBL5908918 | 0.70 | CYP3A4 (0.37) | FDPSSMPD1 | |
| SCHEMBL4874702 | 0.70 | FDPS (0.38) | FDPSGGPS1 | |
| SCHEMBL8193965 | 0.69 | FDPS (0.39) | FDPSGGPS1LPAR1LPAR3 | |
| SCHEMBL5908957 | 0.69 | CYP3A4 (0.40) | FDPSGGPS1SMPD1 | |
| SCHEMBL4828598 | 0.67 | FDPS (0.41) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL6896476 | 0.67 | FDPS (0.54) | FDPSGGPS1SMPD1LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521783-B1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | claimed |
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10781449-B2 | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-2504435-B1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10421962-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190040385-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TARGETING P53 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-10196637-B2 | Retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10195145-B2 | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-3434773-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2019-01-30 | — | — | EP | disclosed |
| EP-2895608-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO P53 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2504435-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | Quark Pharmaceuticals, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012078536-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142754-A1 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | QUARK PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2012044620-A2 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011163436-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Technical Corporation | 2011-07-21 | — | — | US | disclosed |
| WO-2011084193-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085056-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011072082-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011066475-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | HSPA1A, HSPH1, HSPA8 | FDPS 4458/4885GGPS1 3349/4885SMPD1 2863/4885 |
| US-10195145-B2 | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | HSPH1, FABP1, LRAT | FDPS 2105/4885GGPS1 1239/4885SMPD1 704/4885 |
| US-20120142754-A1 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | MMP1, TIMP3, RNASE1 | FDPS 4481/4885GGPS1 4101/4885SMPD1 251/4885 |
| US-10196637-B2 | Retinoid-lipid drug carrier | RXRA, RXRG, LRAT | FDPS 2170/4885GGPS1 1404/4885SMPD1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.